Accuray (ARAY) Q4 2020 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2020 earnings summary
9 Nov, 2026Executive summary
FY20 returned to profitability with net income of $3.8M, while revenue declined 9% YoY to $382.9M amid lower system sales and COVID-19-related delivery and installation delays.
Backlog rose to $602.7M from $495.6M, but pandemic-related timing delays and expected higher-than-normal age-outs threatened near-term conversion to revenue.
Financial highlights
Revenue was $382.9M, down 9% YoY; gross profit was $149.7M, down 8%, and operating income was $12.5M versus $0.6M in FY19.
Net income was $3.8M versus a $16.4M net loss in FY19; diluted EPS was $0.04 versus a $0.19 loss.
Other expense, net fell to $6.8M from $14.9M, including a non-recurring $13.0M gain on systems contributed to the China JV, partly offset by higher interest expense and FX losses.
Net cash used in operations was $1.5M; cash and cash equivalents increased to $107.6M at June 30, 2020 from $76.8M a year earlier.
Outlook and guidance
COVID-19 delivery and installation delays were expected to continue into FY21 and negatively affect revenue; the duration and extent of the impact could not be reliably estimated.
Management expected sufficient cash resources and anticipated cash flows to fund operations for at least 12 months, while continuing to assess liquidity and debt-covenant compliance amid pandemic uncertainty.
Revenue from 50 China Class A licenses, with estimated value of $115.0M, was delayed; recognition was then expected to begin in H1 FY21, subject to tender-process and pandemic uncertainty.
Latest events from Accuray
- FY13 system-sales weakness and MLC delays drove losses despite service growth.ARAY
Q4 2013 - Revenue and orders rebounded; adjusted EBITDA turned positive, but execution risks remained.ARAY
Q4 2014 - Record Q4 orders and constant-currency gains were offset by FX pressure and execution risks.ARAY
Q4 2015 - Record backlog and $24.6M adjusted EBITDA marked progress despite a $25.5M net loss.ARAY
Q4 2016 - Revenue and margin improved in FY18, but net orders weakened as cancellations and age-outs rose.ARAY
Q4 2018 - Record backlog and Radixact demand met lower revenue, weaker margins and continued losses.ARAY
Q4 2017 - TomoTherapy-led growth lifted revenue, but losses, cash use and conversion risks persisted.ARAY
Q4 2019 - Revenue grew 3%, but debt costs and COVID delays drove a $6.3m net loss.ARAY
Q4 2021 - Revenue grew, but margin compression and persistent cost pressures deepened the loss.ARAY
Q4 2023